Vyome Holdings, Inc. (HIND)
NASDAQ:HIND
HIND Stock Chart & Stats
$5.42
--
Market closed
$5.42
--
Day’s Range― - ―
52-Week Range$1.75 - $305.19
Previous CloseN/A
VolumeN/A
Average Volume (3M)84.75K
Market Cap
$16.28M
Enterprise Value$7.83M
Total Cash (Recent Filing)$4.98M
Total Debt (Recent Filing)$31.26K
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Mar 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.12
Shares Outstanding7,018,528
10 Day Avg. Volume43,520
30 Day Avg. Volume84,755
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.04
Price to Sales (P/S)23.26
P/FCF Ratio-1.98
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue24.49
Enterprise Value/Gross Profit35.79
Enterprise Value/Ebitda-2.86
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.82
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Limited DebtVyome's low leverage reduces immediate balance-sheet refinancing risk relative to many biotech peers. With minimal debt obligations, management has more flexibility to prioritize R&D or pursue strategic restructurings without near-term interest burdens, supporting operational resilience over the next 2-6 months.
Positive Phase 2 Data For VT-1953Statistically significant Phase 2 results for VT-1953 demonstrate clinical signal on key symptom endpoints (malodor, pain, QoL) and favorable tolerability. This durable clinical proof point strengthens the asset's positioning as a potential first-in-class therapy and improves partnerability for Phase 3 and commercialization.
Strategic Repositioning Via Livechain/Humanyze DealThe Livechain acquisition creates a structurally different, high-growth AI HR analytics line that can raise capital independently and pursue an uplisting. Isolating this unit limits Vyome's direct operational exposure while diversifying the company's long-term value creation pathways beyond the core biotech program.
Bears Say
Severe Revenue CollapseA collapse in revenue of this magnitude undermines commercial validation and shrinks operational runway. Reduced top-line inflows constrain reinvestment into trials, weaken negotiating leverage with partners, and materially increase the probability management must seek dilutive financing or asset divestitures over the medium term.
Persistent Negative Operating And Free Cash FlowConsistent annual cash burn signals the company cannot self-fund development or commercialization without external capital. Persistent negative OCF/FCF elevates financing risk, can delay or curtail clinical programs, and increases susceptibility to adverse market conditions or partner dependency in the coming quarters.
Deep Unprofitability And Equity InstabilitySustained net losses and episodes of negative equity erode shareholder value and restrict strategic options. This financial instability raises the likelihood of dilutive financing, impairs hiring and retention, and complicates long-term partnerships or licensing deals absent clear funding sources or durable profitability improvements.
Vyome Holdings News
HIND FAQ
What was Vyome Holdings, Inc.’s price range in the past 12 months?
Vyome Holdings, Inc. lowest stock price was $1.75 and its highest was $305.19 in the past 12 months.
What is Vyome Holdings, Inc.’s market cap?
Vyome Holdings, Inc.’s market cap is $16.28M.
When is Vyome Holdings, Inc.’s upcoming earnings report date?
Vyome Holdings, Inc.’s upcoming earnings report date is Mar 30, 2026 which is in 4 days.
How were Vyome Holdings, Inc.’s earnings last quarter?
Vyome Holdings, Inc. released its earnings results on Nov 18, 2025. The company reported -$3.12 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$3.01.
Is Vyome Holdings, Inc. overvalued?
According to Wall Street analysts Vyome Holdings, Inc.’s price is currently Overvalued.
Does Vyome Holdings, Inc. pay dividends?
Vyome Holdings, Inc. does not currently pay dividends.
What is Vyome Holdings, Inc.’s EPS estimate?
Vyome Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vyome Holdings, Inc. have?
Vyome Holdings, Inc. has 7,018,528 shares outstanding.
What happened to Vyome Holdings, Inc.’s price movement after its last earnings report?
Vyome Holdings, Inc. reported an EPS of -$3.12 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went up 1.844%.
Which hedge fund is a major shareholder of Vyome Holdings, Inc.?
Currently, no hedge funds are holding shares in HIND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vyome Holdings, Inc.
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.
HIND Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several positive achievements, such as revenue growth, cost reductions, improved profit margins, and strategic agreements aimed at enhancing shareholder value. However, it also acknowledged challenges, such as the contraction in revenue over the nine-month period and competition from GLP-1 pharmaceuticals. Overall, the positive aspects slightly outweigh the negative trends.View all HIND earnings summariesTechnical Analysis
Sintx Technologies
―
Helius Medical Technologies
―
Venus Concept
―
Movano
―
Heart Test Laboratories, Inc.
―
Ownership Overview
8.06% Insiders
0.03% Mutual Funds
― Other Institutional Investors
91.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---